Exco InTouch and AstraZeneca collaborate on mHealth programme


Uses mobile phone and web-based technologies to improve condition management for COPD patients

A collaboration between UK-based data capture solution provider Exco InTouch and AstraZeneca has led to the development of an mHealth programme that will improve condition management for patients suffering from chronic obstructive pulmonary disease (COPD).

Me&MyCOPD uses interactive mobile phone and Internet-based health tools to help participants track and manage their condition better. Patients can access personalised coaching and real-time information about their disease and treatment through mobile phones and other web-enabled devices, enabling them to collect, transmit and review their own clinical data.

'Me&MyCOPD will help patients control their condition better and healthcare providers to make more informed decisions, tailoring care pathways to each patient’s individual needs,' said Mark Brincat, Director of Product Strategy, Exco InTouch.

'This translates into improving patient welfare and their quality of life by reducing the number of unplanned hospital admissions and the frequency and severity of exacerbations, decreasing the overall treatment costs at the same time.'

Medical device tracking, patient training, managing clinic visits, offering pulmonary rehabilitations and providing advice on how to manage lifestyle issues have all been incorporated into the programme. Clinically validated assessments are also included to support participants, reducing the probability of exacerbations and ultimately hospitalisations.

'AstraZeneca is at the forefront of designing mHealth programmes to help those suffering from chronic conditions to better manage their health,' said Tim Davis, CEO and founder of Exco InTouch.

'Me&MyCOPD expands understanding of how patients use and respond to various treatment options. This underpins the ‘Intelligent Pharmaceuticals’ strategy adopted by AstraZeneca and is the leading example of how optimised treatment can improve patients’ quality of life and health outcomes.'

You may also like